You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 205041 - 205050 of 207728 results
  1. Mitral Valve Repair System to Percutaneously Treat Moderate to Severe Regurgitation Using Alfieri Edge-to-Edge Technique

    SBC: MEDFREE INC            Topic: NHLBI

    The MEDFREE® Valve Repair System will innovatively improve upon the current market leading MitraClip device, while leveraging and building on the proven percutaneous Alfieri edge-to-edge repair technique. We aim to address this vastly unmet percutaneous structural heart market by delivering a simpler, easier-to-use device in a smaller 12 Fr catheter system that can be used by a single operator.

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Early detection of HCC using noninvasive activity-based nanosensors

    SBC: Glympse Bio, Inc.            Topic: 102

    Project Summary/Abstract Hepatocellular carcinoma (HCC) is the most common primary liver cancer and arises from chronic liver diseases (CLD) including hepatitis B virus (HBV), hepatitis C virus (HCV), alcoholic liver disease (ALD), and nonalcoholic steatohepatitis (NASH). Today, patients with CLDs are at high risk for HCC and are monitored closely by imaging and serum biomarkers, but these platfor ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Low Cost, Rapid Molecular Diagnostic for Chlamydia and Gonorrhea at the Point-of-Care

    SBC: Novel Microdevices, LLC            Topic: NIAID

    PROJECT ABSTRACT: Building on the successes of our Phase 1 SBIR project, we propose to refine and productize our sample-to-answer CT/NG NAAT and to validate the analytical and clinical performance of the assay in the intended use setting in Phase 2 of this SBIR project. ​Chlamydia trachomatis (CT) and ​Neisseria gonorrhoeae ​(NG) infections are the number one and two most commonly reported b ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Continuing Preclinical Development of PPCM Vaginal Contraceptive MPT to IND

    SBC: YASO THERAPEUTICS INCORPORATED            Topic: NICHD

    Women in all economic, social, and cultural circumstances suffer from high rates of unplanned pregnancy, along with a high prevalence and incidence of sexually transmitted diseases. Trends in the United States and lesser developed economies are going in the wrong direction. The availability of a single multipurpose prevention product (MPT) that prevents both unplanned pregnancy and one or more of ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 Diabetes

    SBC: Senseion Therapeutics, Inc.            Topic: 200

    Project Summary/Abstract More than 100 million Americans currently have diabetes or pre-diabetes, a condition that can lead to Type 2 diabetes (T2D) within five years, and that vastly increases adverse cardiovascular events. T2D is characterized by both a loss of insulin sensitivity of target tissues (fat, skeletal muscle, liver) and ultimately, impaired insulin secretion from the pancreatic b-cel ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Genetic Cytology for Ovarian and Endometrial Cancer Screening

    SBC: PAPGENE, INC.            Topic: 102

    DESCRIPTION provided by applicant In this Fast Track application a path to commercialization will be pursued for a breakthrough andquot genetic cytologyandquot test capable of detecting both ovarian and endometrial cancer from routinely collected Pap specimens In deference to the notable success of the Pap test in reducing deaths due to cervical cancer and in reference to the core enabling ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections

    SBC: EXBAQ LLC            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT Two million Healthcare Associated Infections (HAIs) occur per year in the US, killing rt90,000 patients and costing ~$50-100 billion (adjusted by CPI to 2020 dollars). HAIs are the 6th leading cause of death in the US, ahead of diabetes and kidney disease. Reducing HAIs is a top priority of the US Department of Health and Human Services1 and experts have called for novel s ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. First and Only Soft Tissue Support Device to Improve Patient Experience and System Cost in Breast Reconstruction

    SBC: Surgical Innovation Associates, Inc.            Topic: 102

    NOTE: These pages contain proprietary/privileged information. SIA requests that they not be released to personsoutside the Government, except for purposes of review and evaluation. Project Summary/Abstract DuraSorb™ is poised to significantly improve the lives of the over 100,000 US women undergoing post- mastectomy breast reconstruction every year. The current standard of care in implant-based ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. IGF OT IGF RandD NANOEMULSION FORMULATION AND IND ENABLING STUDIES OF A NOVEL CENTER STEM CELL CYTOTOXIC AGENTPERIOD OF PERFORMANCE SEPTEMBER JULY

    SBC: Targagenix, Inc.            Topic: NCI

    The proposed studies will create evaluate and validate the formulation dosing pharmacodynamics cytotoxicity efficacy and toxicology of a nanoemulsion of a novel cancer stem cell CSC cytotoxic drug DHA SBT In vitro and in vivo assays using FACS purified CSCs will be used to assess efficacy to kill differentiated tumor cells and CSCs NE DHA SBT will be administered intravenously ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. CTC Purification System Based on Thermoresponsive NanoSubstrates

    SBC: CYTOLUMINA TECHNOLOGIES CORPORATION, INC            Topic: 100

    DESCRIPTION provided by applicant The goal of this SBIR Phase II proposal is to conduct the advanced development of the rd gen Thermoresponsive NanoVelcro assay in order to achieve rapid purification of circulating tumor cells CTCs from non small cell lung cancer NSCLC patient blood samples paving the way for CTC derived molecular signatures and functional readouts This project is led by ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government